Novartis AG ADR

Yahoo Finance • 10 hours ago

Eli Lilly Presses Pause On Zepbound-Bimagrumab Diabetes Study

This article first appeared on GuruFocus. Eli Lilly (NYSE:LLY) has decided to stop one of its obesity drug combination trials, pressing pause on a study that paired Zepbound (tirzepatide) with bimagrumab, a treatment meant to prevent musc... Full story

Yahoo Finance • 17 hours ago

Tiziana to Advance TZLS-501 - Its Fully Human IL-6R Monoclonal Antibody

Tiziana Life Sciences Ltd. BOSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), today announces it will advance its second asset, a fully human anti-IL-6 receptor (“IL-6R”) mo... Full story

Yahoo Finance • 2 days ago

Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations

Zealand Pharma Press release – No. 14 / 2025 Zealand Pharma appoints Rachel James-Owens as Vice President, Corporate Communications & Media Relations Copenhagen, Denmark, September 24, 2025 - Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 2... Full story

Yahoo Finance • 2 days ago

New Novartis data further support benefits of Kesimpta® in relapsing MS following switch from oral disease modifying therapies

Novartis Pharma AG ARTIOS Phase IIIb, open-label, single-arm, prospective study showed a substantial reduction in disease activity in people with relapsing multiple sclerosis (RMS)following switch to Kesimpta after breakthrough disease* o... Full story

Yahoo Finance • 3 days ago

MLAB Biosciences Expands Scientific Advisory Board with Appointments of Peter Kang and Kathryn Wagner, Deepening Scientific Expertise in Neuromuscular Medicine

NEEDHAM, Mass., Sept. 23, 2025 /PRNewswire/ -- MLAB Biosciences, a biotechnology company pioneering novel therapies for neuromuscular disease, today announced the appointment of Kathryn R. Wagner, M.D., Ph.D. and Peter B. Kang, M.D. to its... Full story

Yahoo Finance • 4 days ago

Roche CEO, pharma execs to meet with Swiss government over US tariffs

By John Revill ZURICH (Reuters) -Roche Chief Executive Thomas Schinecker and other senior executives from the Swiss pharmaceuticals industry will meet with the government on Monday to discuss the threat U.S. tariffs pose to the crucial ex... Full story

Yahoo Finance • 4 days ago

Cellares Appoints Former Kite Global Ops Leader, Christopher McDonald, to Board of Advisors

Pictured: Chris McDonald, newest member of Cellares' Board of Advisors Veteran operations leader, with experience at Amgen, Novartis, AstraZeneca, and Kite/Gilead brings decades of manufacturing, quality, and supply chain expertise to sup... Full story

Yahoo Finance • 6 days ago

Novartis chief eyes ways to end higher US drug prices: media

Novartis already announced in April that it plans to invest $23 billion in the United States over five years (Fabrice COFFRINI) Amid a threat of towering US tariffs, Swiss pharmaceutical giant Novartis is seeking ways to enable Americans... Full story

Yahoo Finance • 6 days ago

Novartis CEO reportedly weighing U.S. price cuts as Trump’s MFN deadline nears

[Novartis] TBE/iStock Editorial via Getty Images Just days ahead of the Trump administration’s Sept. 29 deadline, which requires Big Pharma to lower U.S. drug prices to the level of other developed nations, Novartis (NYSE:NVS [https://see... Full story

Yahoo Finance • 6 days ago

Novartis has stockpiles to withstand potential Trump tariffs, CEO says

ZURICH (Reuters) -Novartis has increased its stockpiles of pharmaceuticals in the United States and is well prepared should its products be hit by President Donald Trump's tariffs, its chief executive said in an interview published on Satu... Full story

Yahoo Finance • 10 days ago

Does the Recent 4.6% Dip Signal Opportunity for Novartis in 2025?

If you are trying to figure out what to do with Novartis stock, you are far from alone. Investors everywhere are wondering whether now is the moment to buy, hold, or look elsewhere, especially with this pharmaceutical giant showing a resil... Full story

Yahoo Finance • 10 days ago

Europe Refractory Epilepsy Treatment Research Report 2025 | Market to More Than Double to Reach $2.82 Billion by 2035, Driven by CBD Growth, Uptake of Neuromodulation Therapies, Strong R&D Pipeline

Company Logo The Europe refractory epilepsy treatment market is anticipated to grow from $1.34 billion in 2024 to $2.82 billion by 2035, with a CAGR of 6.98% from 2025 to 2035. This shift towards personalized treatment leverages advanceme... Full story

Yahoo Finance • 11 days ago

Monte Rosa Rockets 50% on $5.7B Novartis Licensing Deal

This article first appeared on GuruFocus. Novartis (NOVN, Financials) and Monte Rosa Therapeutics (GLUE, Financials) have signed a deal worth up to $5.7 billion to work together on medicines for disorders that affect the immune system. Un... Full story

Yahoo Finance • 11 days ago

Monte Rosa stock rises after pact with Novartis

[Communication concept] Shares of Monte Rosa Therapeutics (NASDAQ: NASDAQ:GLUE [https://seekingalpha.com/symbol/GLUE]) rose after it announced a new collaboration with Novartis (NYSE:NVS [https://seekingalpha.com/symbol/NVS]) to advance t... Full story

Yahoo Finance • 11 days ago

Novartis AG (NVS) Strengthens Cardiovascular Unit with Tourmaline Bio Acquisition

Novartis AG (NYSE:NVS) is one of the best defensive stocks to buy, according to Steve Cohen. On September 9, the company confirmed plans to acquire the New York-based pharmaceutical company Tourmaline Bio for $1.4 billion on a fully dilute... Full story

Yahoo Finance • 11 days ago

Traders Cautious Ahead of Fed Meeting, Driving Muted Premarket Action for US Equity Futures

US equity futures were flat before Monday's opening bell as traders remained on the sidelines ahead PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium... Full story

Yahoo Finance • 11 days ago

Monte Rosa surges premarket on Novartis collaboration deal

Investing.com -- Monte Rosa Therapeutics shares have rallied in premarket trading on Monday, up 65.3% to $7.94 after the biotechnology company announced a new collaboration agreement with Novartis focused on developing molecular glue degra... Full story

Yahoo Finance • 11 days ago

Novartis AG-Sponsored ADR (NYSE:NVS) Presents a Compelling Case for Value Investors

The search for undervalued stocks remains a cornerstone of value investing, a strategy pioneered by Benjamin Graham and later popularized by Warren Buffett. This approach focuses on identifying companies trading below their intrinsic value... Full story

Yahoo Finance • 11 days ago

Novartis, Monte Rosa strike $5.7 billion drug development deal

(Reuters) -Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics signed a licensing deal worth up to $5.7 billion on Monday to develop drugs for immune-mediated diseases. (Reporting by Kamal Choudhury in Bengaluru; Editing b... Full story

Yahoo Finance • 11 days ago

Novartis signs up to $5.7 billion licensing deal with Monte Rosa Therapeutics

(Reuters) - Swiss drugmaker Novartis and drug developer Monte Rosa Therapeutics signed a licensing deal worth up to $5.7 billion on Monday to develop drugs for immune-mediated diseases. Under the agreement, Monte Rosa Therapeutics will re... Full story